- Home
- ENTX
ENTX
Entera Bio Ltd.
as of 12-01-2025 12:55pm EST
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
| Founded: | 2010 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 142.0M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 107.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $3.22 | Next Earning Date: | 11-14-2025 |
| Revenue: | $124,000 | Revenue Growth: | 25.25% |
| Revenue Growth (this year): | -76.33% | Revenue Growth (next year): | N/A |
AI-Powered ENTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare ENTX vs Leading Stocks
See how ENTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENTX Entera Bio Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.